BR112022001037A2 - Métodos para tratamento ou prevenção de cânceres envolvendo a administração de agentes receptores anti-ccr5 - Google Patents

Métodos para tratamento ou prevenção de cânceres envolvendo a administração de agentes receptores anti-ccr5

Info

Publication number
BR112022001037A2
BR112022001037A2 BR112022001037A BR112022001037A BR112022001037A2 BR 112022001037 A2 BR112022001037 A2 BR 112022001037A2 BR 112022001037 A BR112022001037 A BR 112022001037A BR 112022001037 A BR112022001037 A BR 112022001037A BR 112022001037 A2 BR112022001037 A2 BR 112022001037A2
Authority
BR
Brazil
Prior art keywords
administration
treating
methods
ccr5 receptor
preventing cancers
Prior art date
Application number
BR112022001037A
Other languages
English (en)
Inventor
Denis Burger
Scott Kelly
Original Assignee
Cytodyn Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytodyn Inc filed Critical Cytodyn Inc
Publication of BR112022001037A2 publication Critical patent/BR112022001037A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

métodos para tratamento ou prevenção de cânceres envolvendo a administração de agentes receptores anti-ccr5. a presente invenção refere-se ao uso de inibidores competitivos do receptor ccr5, tal como o anticorpo monoclonal leronlimab ou fragmentos de ligação do mesmo no tratamento ou prevenção de câncer.
BR112022001037A 2019-08-02 2020-07-31 Métodos para tratamento ou prevenção de cânceres envolvendo a administração de agentes receptores anti-ccr5 BR112022001037A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962882353P 2019-08-02 2019-08-02
US202063047693P 2020-07-02 2020-07-02
PCT/US2020/044616 WO2021026028A1 (en) 2019-08-02 2020-07-31 Methods for treating or preventing cancers involving the administration of anti-ccr5 receptor agents

Publications (1)

Publication Number Publication Date
BR112022001037A2 true BR112022001037A2 (pt) 2022-06-07

Family

ID=72193578

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022001037A BR112022001037A2 (pt) 2019-08-02 2020-07-31 Métodos para tratamento ou prevenção de cânceres envolvendo a administração de agentes receptores anti-ccr5

Country Status (9)

Country Link
US (1) US20220298249A1 (pt)
EP (1) EP4007603A1 (pt)
JP (1) JP2022542524A (pt)
CN (1) CN114502594A (pt)
AU (1) AU2020324948A1 (pt)
BR (1) BR112022001037A2 (pt)
CA (1) CA3146474A1 (pt)
MX (1) MX2022001411A (pt)
WO (1) WO2021026028A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230220088A1 (en) * 2020-06-23 2023-07-13 Maddon Advisors Llc Anti-CCR5 Monoclonal Antibody-Based Compositions and Methods

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6165793A (en) 1996-03-25 2000-12-26 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6458355B1 (en) 1998-01-22 2002-10-01 Genentech, Inc. Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates
US6365408B1 (en) 1998-06-19 2002-04-02 Maxygen, Inc. Methods of evolving a polynucleotides by mutagenesis and recombination
US7122185B2 (en) 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody
ES2438019T3 (es) 2005-07-22 2014-01-15 Cytodyn, Inc. Procedimientos para reducir la carga viral en pacientes infectados por el VIH-1
RU2420284C2 (ru) * 2006-06-12 2011-06-10 Пфайзер Продактс Инк. Антагонист ccr5 для усиления иммуновосстановительной терапии и лечения оппортунистической инфекции у пациентов с вич
EP3107564A4 (en) * 2014-02-18 2017-08-30 CytoDyn Inc. Use of anti-ccr5 antibodies in graft versus host disease
CA2988650A1 (en) 2015-06-23 2016-12-29 Cytodyn Inc. Inhibition of ccl5 ligand binding to ccr5 receptor and alteration of ccr5/ccl5 axis signaling in inflammation, cancer, autoimmune, and other conditions
WO2018209301A1 (en) * 2017-05-11 2018-11-15 Cytodyn Inc. Methods for treating or preventing graft-versus-host disease involving the administration of anti-ccr5 receptor agents

Also Published As

Publication number Publication date
CA3146474A1 (en) 2021-02-11
WO2021026028A1 (en) 2021-02-11
AU2020324948A1 (en) 2022-02-17
US20220298249A1 (en) 2022-09-22
EP4007603A1 (en) 2022-06-08
JP2022542524A (ja) 2022-10-04
CN114502594A (zh) 2022-05-13
MX2022001411A (es) 2022-03-25

Similar Documents

Publication Publication Date Title
CY1124791T1 (el) Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων
PH12019501663A1 (en) Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
MX2017015811A (es) Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4).
PH12018500642A1 (en) Anti-garp antibody
MX2022004000A (es) Uso de un anticuerpo de muerte anti-programada 1 (anti-pd-1) en combinacion con una quimioterapia doble a base de platino (pt-dc) para el tratamiento de cancer de pulmon.
MX2019008207A (es) Métodos para tratar el cáncer con anticuerpos anti-pd-1.
MX2018013848A (es) Combinacion de anticuerpos anti-pd-1s y radiacion para tratar cancer.
BR112014018481A2 (pt) anticorpo monoclonal ou policlonal ou um fragmento de ligação a antígeno do mesmo, polinucleotídeo, anticorpo monoclonal, vetor, hibridoma, anticorpo, hibridoma 5166-2 e/ou 5166-9, anticorpo ou fragmento de ligação a antígeno, composição farmacêutica, uso do anticorpo ou fragmento de ligação a anticorpo, método para tratar câncer, método para diagnosticar câncer em um indivíduo, anticorpo, método, composição ou uso
MY176475A (en) Human antibodies to pd-1
EA200970317A1 (ru) Комбинированное лечение опухолей, экспрессирующих cd38
MX2020008445A (es) Metodos para tratar el cancer con anticuerpos anti-pd-1.
MX2023002554A (es) Anticuerpos anti-il-1r3 humanizados.
MX2020006116A (es) Terapia combinada de agonistas de icos dirigidos a tumores con moleculas biespecificas de linfocitos t.
PH12020551661A1 (en) Anti-pd-l1 antibody and use thereof
EA201992318A1 (ru) Композиции и способы для диагностики и лечения рака предстательной железы с использованием молекулы, связывающей прогастрин
BR112017011538A2 (pt) combinação de anticorpos anti-cs1 e anti-pd1 para tratar câncer (mieloma)
EP3991749A3 (en) A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody
BR112016023011A2 (pt) tratamento de câncer gástrico
BR112022001037A2 (pt) Métodos para tratamento ou prevenção de cânceres envolvendo a administração de agentes receptores anti-ccr5
EA202090741A1 (ru) Конъюгаты антитела к тканевому фактору и лекарственного средства и их применение в лечении рака
EA201991870A1 (ru) Лечение рака мочевого пузыря с помощью антитела к pd-l1
ZA201907754B (en) Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer
MX2020011377A (es) Metodos y composiciones para el tratamiento de urticaria cronica.
MX2022005400A (es) Metodos de diagnostico y terapeuticos para el tratamiento de canceres hematologicos.
EA202092481A1 (ru) Комбинированный способ лечения антагонистом cd73 и антагонистом оси pd-1/pd-l1